Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Sean Michael Grimmond

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8102-7998; OpenAlex author ID A5040120471. Sources: OpenAlex.

Their work

Papers
36 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
115
Papers, trials and grants by year

2012: 3 papers · 2013: 2 papers · 2014: 8 papers · 2015: 5 papers · 2016: none · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 36

  1. Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma. Co-author DOI 10.1055/a-2733-1068↗
  2. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  3. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  4. S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer. Co-author DOI 10.1038/s41418-023-01126-z↗
  5. Correction to: S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer. Co-author DOI 10.1038/s41418-023-01151-y↗
  6. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  7. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  8. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  9. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  10. The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. Co-author DOI 10.3390/cancers13194979↗
  11. PRMT5: An Emerging Target for Pancreatic Adenocarcinoma. First author DOI 10.3390/cancers13205136↗
  12. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  13. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  14. Exome-Wide Association Study of Pancreatic Cancer Risk. Co-author DOI 10.1053/j.gastro.2017.10.015↗
  15. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  16. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ng.3861↗
  17. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  18. Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Co-author DOI 10.1186/s40170-017-0164-1↗
  19. Whole genomes redefine the mutational landscape of pancreatic cancer. Last author DOI 10.1038/nature14169↗
  20. Pancreatic cancer genomics: where can the science take us? Co-author DOI 10.1111/cge.12536↗
  21. SOX9 regulates ERBB signalling in pancreatic cancer development. Co-author DOI 10.1136/gutjnl-2014-307075↗
  22. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Co-author DOI 10.1158/1078-0432.ccr-15-0426↗
  23. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. Co-author DOI 10.1200/jco.2013.51.5783↗
  24. Clinical and pathologic features of familial pancreatic cancer. Co-author DOI 10.1002/cncr.28863↗
  25. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Last author DOI 10.1002/ijc.28765↗
  26. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Co-author DOI 10.1016/j.cell.2014.01.066↗
  27. Pancreatic cancer genomics. First author DOI 10.1016/j.gde.2013.12.001↗
  28. Targeting mTOR dependency in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2013-306202↗
  29. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-0048↗
  30. Returning individual research results for genome sequences of pancreatic cancer. Co-author DOI 10.1186/gm558↗
  31. Can we move towards personalised pancreatic cancer therapy? Co-author DOI 10.1586/17474124.2014.893820↗
  32. Understanding pancreatic cancer genomes. Co-author DOI 10.1007/s00534-013-0610-6↗
  33. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Co-author DOI 10.1186/gm482↗
  34. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nature11114↗
  35. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1202490109↗
  36. RON is not a prognostic marker for resectable pancreatic cancer. Co-author DOI 10.1186/1471-2407-12-395↗

Closest collaborators

The 25 strongest of 115 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Victor Biankin · 22 shared papers, 2012–2021 · strength 0.95
  2. Belinda Lee · 4 shared papers, 2021–2026 · strength 0.65
  3. David Kuang-Fu Chang · 15 shared papers, 2012–2018 · strength 0.60
  4. Marina Pajic · 11 shared papers, 2013–2021 · strength 0.46
  5. Ronnie Ren Jie Low · 3 shared papers, 2021–2023 · strength 0.42
  6. Tracy L. Putoczki · 3 shared papers, 2021–2023 · strength 0.42
  7. Peter Gibbs · 3 shared papers, 2021–2023 · strength 0.42
  8. Amber L. Johns · 8 shared papers, 2013–2021 · strength 0.32
  9. Anthony James Gill · 8 shared papers, 2012–2021 · strength 0.31
  10. Mark J. Cowley · 8 shared papers, 2012–2018 · strength 0.30
  11. Jaswinder Singh Samra · 6 shared papers, 2013–2021 · strength 0.26
  12. Angela S. Y. Chou · 6 shared papers, 2012–2021 · strength 0.26
  13. Owen McKay · 1 shared paper, 2026 · strength 0.23
  14. John Raymond Zalcberg · 1 shared paper, 2026 · strength 0.23
  15. Joanne Lundy · 1 shared paper, 2026 · strength 0.23
  16. Daniel Gerald Croagh · 1 shared paper, 2026 · strength 0.23
  17. Manoop S. Bhutani · 1 shared paper, 2026 · strength 0.23
  18. Brendan John Jenkins · 1 shared paper, 2026 · strength 0.23
  19. Adnan M. Nagrial · 6 shared papers, 2013–2018 · strength 0.23
  20. Michael K.C. Lee · 1 shared paper, 2021 · strength 0.19
  21. Karen E. Sheppard · 1 shared paper, 2021 · strength 0.19
  22. Jennifer P. Morton · 3 shared papers, 2014–2021 · strength 0.16
  23. Owen James Sansom · 3 shared papers, 2014–2021 · strength 0.16
  24. Nigel Balfour Jamieson · 3 shared papers, 2014–2015 · strength 0.15
  25. Venessa T. Chin · 4 shared papers, 2013–2018 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.